Can a skin cream really reverse its biological age? The early RLS-1496 story

The claim behind the headline

In October 2026, Rubedo Life Sciences publicised early results from its investigational skin treatment RLS-1496. The company said treated samples from people with atopic dermatitis showed a lower epigenetic age measurement after a short course. Epigenetic clocks estimate aspects of biological ageing from chemical marks on DNA. They are research measurements, not a direct way to watch the clock of a person's life run backwards.

Rubedo's investor news archive lists the October announcement. It describes a fall of about 2.1 years in a small set of paired skin samples. This is company-reported preliminary data, not independently established evidence that an anti-ageing cream works.

What was actually studied?

An EU clinical-trial record identifies a phase 1 study of topical RLS-1496 involving people with plaque psoriasis or atopic dermatitis. Its purpose was early human investigation, including safety, not to prove that healthy skin could be 'rejuvenated'. The EU record lists a trial start in April 2025 and an end in March 2026.

A separate US trial registration describes study of the same cream in actinic keratosis, sun-damaged skin lesions that can require medical assessment. The study examines safety and lesion counts on treated and comparison skin areas. That does not make the cream a proven cosmetic treatment for ordinary wrinkles.

These are distinct groups and research questions. A result in a clinical skin condition may not translate to people simply wanting smoother, younger-looking skin.

Why 'two years younger' can mislead

A molecular clock result is not the same as seeing a change in deep wrinkles, skin elasticity, patient wellbeing or the future chance of skin cancer. A clock can move without someone looking different. Small samples also make results sensitive to which people were included and how measurements were analysed.

The headline measure here comes from a limited set of paired skin samples, not a large independently replicated trial. Without fuller controlled results, we cannot tell how much of the change is specifically due to the treatment or how long it lasts.

There is another crucial difference: targeting a cellular process associated with ageing is not the same as slowing the ageing of an entire person. A treatment could prove useful for one skin condition without becoming a general longevity therapy.

Is this something you can buy?

No established consumer anti-ageing product is being evaluated here. RLS-1496 is an investigational drug candidate, not a routine moisturiser or serum. The trial registries describe research, not a licensed shop product.

Be wary of unrelated products claiming to be 'senolytic' or to reset skin age because they use similar language. Brand advertising and trial registrations are not interchangeable with evidence of clinical benefit.

The questions we want answered next

A convincing next step would include adequately sized controlled studies, reproducible measurement, meaningful patient outcomes and longer follow-up. How often does irritation occur? Does an improvement in a laboratory clock track visible or functional changes? What happens after treatment stops? Will independent investigators reproduce the findings?

The company's financial interest in its own product should also be plain to readers. That is common in drug development, but stronger evidence requires more than a manufacturer's press release.

Sources and conflicts

Clinical trial registries provide the study settings and status. Rubedo's results are explicitly identified as the developer's preliminary claims. Ageless Ape has no commercial relationship with Rubedo; no branded product image or clinical before-and-after imagery is used.